Within this variation, a specific tsRNA (tRF-60:76-Val-AAC-1-M5) influences the therapeutic heterogeneity of sacubitril/valsartan by targeting Tnfrsf10b (tumor necrosis factor receptor superfamily 10B) and Bcl2l1 (BCL2-like 1) in lipid and atherosclerosis signaling pathways.19 This evidence concerns the gene BCL2L1 and atherosclerosis.